A detailed history of Engineers Gate Manager LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Engineers Gate Manager LP holds 1,686 shares of BGNE stock, worth $306,211. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,686
Holding current value
$306,211
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $242,665 - $378,523
1,686 New
1,686 $378,000
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $440,935 - $659,746
2,473 Added 252.09%
3,454 $615,000
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $211,434 - $269,284
981 New
981 $211,000
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $225,246 - $345,628
1,709 New
1,709 $230,000
Q1 2020

May 15, 2020

SELL
$121.84 - $173.19 $609,443 - $866,296
-5,002 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$115.78 - $208.34 $579,131 - $1.04 Million
5,002 New
5,002 $829,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.8B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.